Non-Member Access fee for Recorded CE Webinar:
Come Together Right Now: Connecting Lipid Guidelines with Novel Non-Statin Therapies
Non-members are invited to view recorded webinars and receive CE credit for a small fee.
Once your payment has been processed, you will receive an automated email with a link to download an electronic item. Click the link in the email - this will download a PDF file that contains a link to access the recorded webinar.
Please contact PPA's CPE Administrator, Sara Powers, at (717) 234-6151 x. 2 or firstname.lastname@example.org with questions.
Please read the following information about this continuing pharmacy education (CPE) activity before viewing the presentation.
Release Date: January 30, 2016
Expiration Date: January 30, 2019
Activity Type: Application-based
CE Credit: 1.5 Contact Hours (0.15 CEU)
Cost: Free for PPA members! $45 for non-members.
|The Pennsylvania Pharmacists Association is accredited by the Accreditation
Council for Pharmacy Education as a provider of continuing pharmacy education.
Primarily clinical pharmacists; however, all pharmacists may benefit as hyperlipidemia management is encountered in all areas of pharmacy practice
The release of the ACC/AHA Lipid Guidelines in 2013 changed clinical practice by moving away from LDL-C specific goals and emphasizing statin therapy for all at-risk patients. With the recent FDA approval of PSCK9 inhibitors into the US pharmaceutical market, there is question as to where these extremely potent LDL-C reducing drugs fit into current guidelines. This program will discuss the evidence behind the use of PCSK9 inhibitors and other non-statin therapies in high-risk patients and debate where these agents fit into current practice.
1. Review the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2. Compare and contrast current lipid guidelines with the ATP III guidelines; discuss existing controversies
3. Review the evidence regarding the use of non-statin therapies in high risk patients, including those with familial hypercholesteremia
4. Discuss the mechanism, dosing, efficacy, and safety of PSCK9 inhibitors
5. Debate where PSCK9 inhibitors and other non-statin therapies should fit into current lipid guidelines and apply learned concepts to patient cases
Kimberly L. Carter, PharmD, BCACP, Assistant Professor, Jefferson College of Pharmacy
Kimberly Carter is an Assistant Professor at the Jefferson School of Pharmacy in Philadelphia, PA. She obtained her PharmD degree from The University of Tennessee in 2009 and completed an Ambulatory Care PGY2 residency at The Johns Hopkins Hospital in 2011. Her current clinical practice site is at Penn Center for Primary Care in West Philadelphia where she serves as an ambulatory care pharmacist and preceptor. Her clinical areas of interest include type 2 diabetes management, hypertension, cardiovascular risk reduction, and assisting non-English speaking refugee patients with pharmacotherapy management.
To receive CE credit for this home study, you will need to watch the entire video, complete an online survey evaluation, and pass a short quiz. Access to the survey and quiz will be automatically provided after you have watched the video. PPA must have your CPE Monitor ID and birthday on file to issue credit.